210 related articles for article (PubMed ID: 12948849)
1. Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects.
Bock KW
Biochem Pharmacol; 2003 Sep; 66(5):691-6. PubMed ID: 12948849
[TBL] [Abstract][Full Text] [Related]
2. The UDP-glycosyltransferase (UGT) superfamily expressed in humans, insects and plants: Animal-plant arms-race and co-evolution.
Bock KW
Biochem Pharmacol; 2016 Jan; 99():11-7. PubMed ID: 26453144
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of the UDP-glucuronosyltransferase transcriptome in human tissues.
Zhou L; Montalvo AD; Collins JM; Wang D
Pharmacol Res Perspect; 2023 Dec; 11(6):e01154. PubMed ID: 37983911
[TBL] [Abstract][Full Text] [Related]
4. Characterization of UDP-Glucuronosyltransferases and the Potential Contribution to Nicotine Tolerance in
Pan Y; Xu P; Zeng X; Liu X; Shang Q
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31349586
[TBL] [Abstract][Full Text] [Related]
5. UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: A systematic review of UGT isoforms for precision medicine.
Yang N; Sun R; Liao X; Aa J; Wang G
Pharmacol Res; 2017 Jul; 121():169-183. PubMed ID: 28479371
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
Miners JO; McKinnon RA; Mackenzie PI
Toxicology; 2002 Dec; 181-182():453-6. PubMed ID: 12505351
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.
Iyanagi T
Int Rev Cytol; 2007; 260():35-112. PubMed ID: 17482904
[TBL] [Abstract][Full Text] [Related]
8. The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily.
Meech R; Miners JO; Lewis BC; Mackenzie PI
Pharmacol Ther; 2012 May; 134(2):200-18. PubMed ID: 22322248
[TBL] [Abstract][Full Text] [Related]
9. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions.
Bock KW; Köhle C
Biochem Pharmacol; 2009 May; 77(9):1458-65. PubMed ID: 19150343
[TBL] [Abstract][Full Text] [Related]
10. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP-glucuronosyltransferases.
Batt AM; Magdalou J; Vincent-Viry M; Ouzzine M; Fournel-Gigleux S; Galteau MM; Siest G
Clin Chim Acta; 1994 May; 226(2):171-90. PubMed ID: 7923812
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the zebrafish Ugt repertoire reveals a new class of drug-metabolizing UDP glucuronosyltransferases.
Wang Y; Huang H; Wu Q
Mol Pharmacol; 2014 Jul; 86(1):62-75. PubMed ID: 24728488
[TBL] [Abstract][Full Text] [Related]
12. Potential genoprotective role for UDP-glucuronosyltransferases in chemical carcinogenesis: initiation of micronuclei by benzo(a)pyrene and benzo(e)pyrene in UDP-glucuronosyltransferase-deficient cultured rat skin fibroblasts.
Vienneau DS; DeBoni U; Wells PG
Cancer Res; 1995 Mar; 55(5):1045-51. PubMed ID: 7866987
[TBL] [Abstract][Full Text] [Related]
13. The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families.
Radominska-Pandya A; Bratton SM; Redinbo MR; Miley MJ
Drug Metab Rev; 2010 Feb; 42(1):133-44. PubMed ID: 19821783
[TBL] [Abstract][Full Text] [Related]
14. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
[TBL] [Abstract][Full Text] [Related]
15. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast.
Oda S; Fujiwara R; Kutsuno Y; Fukami T; Itoh T; Yokoi T; Nakajima M
Drug Metab Dispos; 2015 Jun; 43(6):812-8. PubMed ID: 25834030
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Mammalian UDP-Glucuronosyltransferases.
Wang H; Cao G; Wang G; Hao H
Curr Drug Metab; 2018; 19(6):490-501. PubMed ID: 29521218
[TBL] [Abstract][Full Text] [Related]
17. Rapid and convenient biotransformation procedure for human drug metabolizing enzymes using permeabilized fission yeast cells.
Sharma S; Durairaj P; Bureik M
Anal Biochem; 2020 Oct; 607():113704. PubMed ID: 32697953
[TBL] [Abstract][Full Text] [Related]
18. [Review on gene polymorphisms of UDP-glucuronosyltransferases and genetic susceptibility of cancer].
Wang Y; Zheng Y
Wei Sheng Yan Jiu; 2008 Sep; 37(5):629-32. PubMed ID: 19069670
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.
Guillemette C
Pharmacogenomics J; 2003; 3(3):136-58. PubMed ID: 12815363
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7.
Miley MJ; Zielinska AK; Keenan JE; Bratton SM; Radominska-Pandya A; Redinbo MR
J Mol Biol; 2007 Jun; 369(2):498-511. PubMed ID: 17442341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
